by Katrina Rogers | Jun 27, 2019 | Uncategorized
On June 3rd the FDAs Oncology Center for Excellence announced the launch of a new call center known as Project Facilitate to increase access to unapproved oncology therapies for use in patients who are not eligible for the clinical trial(s) for those therapies....
by Katrina Rogers | Jun 25, 2019 | Uncategorized
Expediting Development of Oncology TherapeuticsConferees at the American Association of Cancer Research in March had the chance to hear about master clinical trial protocols from Marc Theoret, who is the Lead Medical Officer in the Office of Oncology Drug Products at...
by Katrina Rogers | Jun 23, 2019 | Uncategorized
Dear Readers:As summer starts, I’ll be reducing the frequency of my posts to give me a bit of extra time for some fun. Look for my updates twice a week (on Tuesdays and Thursdays) and be sure to contact me if you have a topic you’d like me to look...
by Katrina Rogers | Jun 20, 2019 | Uncategorized
Regular readers will recall my previous post on framework for Real World Data (RWD)/Real World Evidence (RWE) and its potential role(s) in drug approvals. Patient-Reported Outcomes Measures (PROM) can fill a similar role in medical device submissions. A PROM is a...
by Katrina Rogers | Jun 18, 2019 | Uncategorized
The FDA’s Pre-Submission (Pre-Sub) program allows sponsors to request feedback from the agency on their planned medical device submissions. The original Pre-Sub guidance (issued in 2014 and updated in 2017) described 6 specific mechanisms for...
Recent Comments